Clinical characteristics of the study population
| Infliximab-treated patients with IBD (n=86) | ||
|---|---|---|
| Median age (IQR 25–75, range) | 31 (24.5–39.5, 4–70) | |
| Type of IBD | Crohn’s disease | 59 (69%) |
| UC | 24 (28%) | |
| IBD colitis-unclassified | 3 (3.5%) | |
| Median age, years (IQR 25–75, range) | 31 (24.5–39.5, 4–70) | |
| Median duration of IFX therapy, months (IQR 25–75, range) | 7 (4–18.5, 0.5–66) | |
| Dose of IFX | 5 mg/kg/8 weeks | 72 (84%) |
| Intensified dose | 14 (16%) | |
| Concomitant immunomodulators* | Yes | 37 (43%) |
| No | 49 (57%) | |
| Dosing pattern | Scheduled | 72 (84%) |
| Episodic | 14 (16%) | |
| ATI status | Positive | 56 (65%) |
| Negative | 30 (35%) | |
| Additional controls | Healthy individuals | 14 |
| Non-IFX-treated IBD | 5 | |
| Patients with rheumatologic diseases | 3 | |
*Immunomodulators were thiopurines in 29 patients, MTX in 4 and prednisone in 4.
ATI, antibodies to infliximab; IFX, infliximab; MTX, methotrexate.